KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Efficacy and safety of albumin-bound paclitaxel combined with simvastatin in the second-line treatment of small cell lung cancer: a phase II randomized controlled trial. PMID 41937137 · BMC Med · 2026-Apr-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of topical finasteride spray solution in the treatment of Chinese men with androgenetic alopecia: A phase III, multicenter, randomized, double-blind, placebo-controlled study. PMID 40090937 · Chin Med J (Engl) · 2026-Apr-05 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Comparative long-term sedation efficacy of remimazolam vs propofol in malignant patients with mechanical ventilation: an exploratory non-inferiority randomized study. PMID 41935116 · Sci Rep · 2026-Apr-04 The record does not meet the eligibility criteria. While it is an oncology, human, randomized, drug-intervention trial with original results, the required Phase III/IIIb or Phase II/III evidence is not established from the provided metadata. Furthermore, the primary endpoint is not a time-to-event efficacy endpoint (OS, PFS, etc.) suitable for Kaplan-Meier digitization.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Validating National Registry Data for Randomised Trials: Comparison of registry-derived cardiovascular events with and without adjudication in the BETAMI-DANBLOCK trial. PMID 41934630 · Eur Heart J Qual Care Clin Outcomes · 2026-Apr-04 The trial is a cardiovascular registry-based randomized trial for beta-blocker therapy in myocardial infarction patients, not an oncology study.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of Time of Administration, Fasting, and a Low-Carbohydrate Diet on Alpelisib-Associated Hyperglycemia and Efficacy: A Pilot Randomized Controlled Phase IIb Trial. PMID 41976378 · Cancers (Basel) · 2026-Apr-03 The trial is a Phase IIb randomized study (not Phase III/IIIb or Phase II/III) and its primary endpoint is an incidence rate (EAIR) of a safety/toxicity outcome (hyperglycemia), not a primary/key time-to-event efficacy endpoint like OS, PFS, etc. While efficacy is mentioned as a secondary endpoint, it is not defined as a time-to-event outcome in the abstract, nor are KM curves or HRs reported.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The efficacy of combined bandage contact lens and nasal margin suture fixation in pterygium patients and its impact on inflammatory cytokines. PMID 41933093 · Sci Rep · 2026-Apr-03 The study is not an oncology trial; it investigates pterygium (a benign ocular surface condition) using surgical and suture techniques, not a drug intervention for malignant neoplasms. It lacks a primary time-to-event efficacy endpoint (e.g., OS, PFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Megestrol acetate versus dexamethasone to prevent nausea and vomiting in patients with gastric or gastro-oesophageal junction cancer treated with oxaliplatin-based chemotherapy: study protocol of a multicentre, randomised, non-inferiority trial. PMID 41932699 · BMJ Open · 2026-Apr-03 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Vaginal natural orifice transluminal endoscopic surgery versus laparoscopy for ovarian cystectomy: a prospective, open-label, randomized, non-inferiority pilot trial. PMID 41931151 · Arch Gynecol Obstet · 2026-Apr-03 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Phase I Clinical Study of DOC1021 (dubodencel) for Adjuvant Immunotherapy of Glioblastoma. PMID 41959823 · medRxiv · 2026-Apr-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Subarachnoid Hemorrhage: Clazosentan vs. Fasudil for Vasospasm Prevention (SAVIOR) Study: Study Protocol for a Prospective, Multicenter, Randomized Trial. PMID 41927991 · Neurocrit Care · 2026-Apr-02 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Association between screening duration and treatment outcomes in the clinical trials of ranibizumab and aflibercept for neovascular age-related macular degeneration. PMID 41927600 · Sci Rep · 2026-Apr-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Stereotactic ablative radiotherapy versus video-assisted lobectomy for operable stage I non-small-cell lung cancer: study protocol for an emulated target trial. PMID 41927289 · BMJ Open · 2026-Apr-02 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Anesthetic approaches and 2-year recurrence rates in non-muscle invasive bladder cancer: a randomized clinical trial. PMID 39740955 · Reg Anesth Pain Med · 2026-Apr-02 The study is an oncology RCT with time-to-event outcomes, but the intervention compares anesthesia techniques (spinal vs. general), not a drug-containing regimen. It lacks explicit Phase III/IIIb or Phase II/III evidence.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase II trial of hepatic arterial infusion chemotherapy plus bevacizumab and toripalimab for advanced biliary tract cancers: efficacy, safety, and exploratory analysis. PMID 41983220 · Hepatobiliary Surg Nutr · 2026-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab). PMID 41960901 · Cancer Res Commun · 2026-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The Prognostic Impact of Supraclavicular Lymph Node Metastases in Lung Cancer: Do We Need a Modification of the Current Staging System? PMID 41945947 · Asian Pac J Cancer Prev · 2026-Apr-01 This is a retrospective observational study of Stage IIIB NSCLC patients receiving chemoradiation therapy. It is not a randomized trial, does not specify a drug-containing intervention, and is not a Phase III/IIIb or Phase II/III trial. It is a prognostic analysis with time-to-event endpoints (PFS, OS), but does not meet the eligibility criteria for a randomized drug trial.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Longitudinal Patterns of Symptoms in Patients Undergoing Chemotherapy: A Secondary Analysis of a Cluster Randomized Clinical Trial. PMID 41941188 · JAMA Netw Open · 2026-Apr-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Apolipoprotein E Mimetic Peptide CN-105 and Postoperative Delirium in Older Patients: The Phase 2 MARBLE Randomized Clinical Trial. PMID 41931297 · JAMA Netw Open · 2026-Apr-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of dexmedetomidine on recovery of postoperative gastrointestinal function in patients with adhesive bowel obstruction: a single-center randomized clinical trial. PMID 41917824 · BMC Anesthesiol · 2026-Apr-01 The study is not in oncology (malignant neoplasm). It investigates postoperative GI function recovery in adhesive bowel obstruction, which is a non-malignant, non-oncologic condition. Therefore, it fails the fundamental oncology criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparative efficacy of pharmacologic therapies for MASLD in improving fibrosis: systematic review and network meta-analysis. PMID 41811770 · Eur J Gastroenterol Hepatol · 2026-Apr-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
First-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer: Three-Year Follow-Up of the Phase 3 RATIONALE-309 Randomized Clinical Trial. PMID 41746630 · JAMA Oncol · 2026-Apr-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial. PMID 41746629 · JAMA Oncol · 2026-Apr-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Phase 2b trial of inhaled imatinib for treatment of pulmonary arterial hypertension. PMID 41738079 · Am J Respir Crit Care Med · 2026-Apr-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer: A Randomized Clinical Trial. PMID 41712229 · JAMA Oncol · 2026-Apr-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension. PMID 41706476 · JAMA Dermatol · 2026-Apr-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Dupilumab in Patients With Chronic Spontaneous Urticaria: Phase 3 LIBERTY-CSU CUPID Randomized Clinical Trials. PMID 41706458 · JAMA Dermatol · 2026-Apr-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study. PMID 41697690 · JAMA Neurol · 2026-Apr-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of Neostigmine on Attenuation of Proinflammatory Cytokines When Given as an Adjuvant Therapy in Septic Shock: A Randomized Control Trial. PMID 41677407 · Crit Care Med · 2026-Apr-01 The study is a randomized, placebo-controlled trial in septic shock, not in oncology. The primary endpoint is an inflammatory biomarker (Tumor Necrosis Factor-alpha), and while 28-day mortality is reported, it is a secondary endpoint without KM plot or HR analysis provided in the abstract. Therefore, it does not meet the core oncology or time-to-event endpoint criteria for the cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cognitive-Behavioral Sleep and Nutritional Intervention Enhances Recovery and Survival in Rectal Cancer Patients Undergoing Abdominoperineal Resection: A Randomized Controlled Trial. PMID 41642757 · Biopsychosoc Sci Med · 2026-Apr-01 Eligible on most criteria (oncology, human, randomized, time-to-event), but excluded because the intervention is non-drug-only (behavioral and nutritional) and no drug-containing intervention is present. The trial phase is also not explicitly stated as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial. PMID 41627802 · JAMA Intern Med · 2026-Apr-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Investigator-led clinical trial of boron neutron capture therapy system for recurrent high-grade meningiomas after radiation therapy: Randomized phase II study. PMID 41560342 · Neuro Oncol · 2026-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Correction to: Randomized, Double-Blind, Active-Controlled Phase 3 Study to Evaluate Efficacy and Safety of Zastaprazan Compared to Esomeprazole in Erosive Esophagitis. PMID 41556513 · Am J Gastroenterol · 2026-Apr-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Vitamin D for tuberculosis or acute respiratory infections: lost in translation? PMID 41549871 · Curr Opin Infect Dis · 2026-Apr-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial. PMID 41537701 · Clin Cancer Res · 2026-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Conditional recurrence-free survival after curative esophagectomy: individual patient data analysis of 11 trials. PMID 41500250 · J Natl Cancer Inst · 2026-Apr-01 This is an individual patient data meta-analysis of multiple RCTs, not a primary report of a single trial with a drug intervention. While it analyzes phase III trials, it is a secondary analysis, and the original trials are not individually reported here with their drug-specific results. The study focuses on statistical methodology (conditional survival) rather than reporting the efficacy of a specific drug intervention.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy. PMID 41428405 · Clin J Am Soc Nephrol · 2026-Apr-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiation Therapy in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD). PMID 41422917 · Int J Radiat Oncol Biol Phys · 2026-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Prospective, randomized dose-escalation trial with proton-based radiation for skull base and cervical spine chondrosarcomas: 30-year outcomes from PROG 85-26. PMID 41414803 · Neuro Oncol · 2026-Apr-01 The study is a randomized trial reporting time-to-event efficacy results, but it lacks an explicit drug-containing intervention and does not clearly establish a definitive Phase III/IIIb or Phase II/III status.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Phase III Randomized Controlled Trial of Pyloroplasty Versus No Pyloroplasty in Patients Undergoing Minimally Invasive Esophagectomy or Robot-assisted Minimally Invasive Esophagectomy. PMID 41413794 · Ann Surg · 2026-Apr-01 干预为非药物单独策略,未满足药物干预要求。
H L B
旧查询独有 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Validity and Psychometric Properties of 3 and 4 Visual Analog Scale in Participants With Psoriatic Arthritis Treated With Guselkumab. PMID 41326161 · J Rheumatol · 2026-Apr-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Quality of Life of Stereotactic Versus Hypofractionated Radiation Therapy for Inoperable Stage I Non-Small Cell Lung Cancer: Results From the LUSTRE Trial. PMID 41275977 · Int J Radiat Oncol Biol Phys · 2026-Apr-01 The report is a Phase III randomized trial in human oncology, but the intervention is non-drug-only (stereotactic vs. hypofractionated radiation therapy) and the primary endpoint is quality-of-life, not a time-to-event efficacy outcome (e.g., OS, PFS). Therefore, it does not meet the eligibility criteria for a drug-containing intervention with a primary/key secondary time-to-event endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Artificial Intelligence Analysis of Endoscopy Outperforms Conventional Endoscopic Scoring for Agreement With Symptoms and Quality of Life in a Phase 3 Ulcerative Colitis Trial. PMID 41247057 · Am J Gastroenterol · 2026-Apr-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Controlled trial of cervical cancer screening frequency among human-papillomavirus-vaccinated women. PMID 41203578 · Int J Cancer · 2026-Apr-01 The record describes a randomized trial in cervical cancer screening frequency among HPV-vaccinated women. It meets criteria for oncology, human, randomized, time-to-event, and original result. However, the intervention is a screening frequency (low- vs. high-intensity cytology), not a drug-containing therapeutic intervention. The trial phase is not explicitly stated as Phase III/IIIb or II/III; the metadata lacks definitive phase information. Therefore, it is ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Exclusion of patients with renal impairment from phase 3 randomized controlled trials in hematologic malignancies. PMID 41195829 · Int J Cancer · 2026-Apr-01 The record describes a meta-analytic study examining the exclusion of patients with renal impairment from phase 3 RCTs in hematologic malignancies. While it is oncology, human, randomized, phase 3, and involves drug interventions, it is not an original result report of a single trial. It lacks a primary time-to-event efficacy endpoint, as its outcomes are about trial design (eligibility criteria), not patient outcomes like OS or PFS. Therefore, it is excluded.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Postoperative Single-Fraction Stereotactic Partial Breast Irradiation for Early-Stage Breast Cancer With GammaPod Technology: A Phase 2 Clinical Trial. PMID 41161644 · Int J Radiat Oncol Biol Phys · 2026-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Electro-acupuncture for quality of life during adjuvant chemotherapy in gastric cancer: a randomized trial. PMID 41143548 · J Natl Cancer Inst · 2026-Apr-01 The study is excluded because the primary intervention under evaluation is electro-acupuncture (a non-drug modality), not a drug-containing intervention, which is a required criterion. Additionally, the trial phase is not definitively established as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Five-Year Survival and Safety of SABR in Patients with Unresectable Locally Advanced Non-Small Cell Lung Cancer unfit for Concurrent Radio-chemotherapy: Focus on Patterns of Local Recurrence from the START-NEW-ERA Non-randomized Phase 2 Trial. PMID 40992670 · Int J Radiat Oncol Biol Phys · 2026-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The National Health Service-Galleri multicancer screening trial: explanation and justification of unique and important design issues. PMID 40795803 · J Natl Cancer Inst · 2026-Apr-01 The record is an explanatory article about the NHS-Galleri screening trial's design and justification. While it is an oncology RCT in humans with a definitive (Phase III) screening design, it does not meet two core eligibility criteria: (1) it lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR), as its primary outcome is late-stage cancer incidence, which is a diagnostic/screening endpoint; and (2) the intervention is a diagnostic test, not a drug-containing intervention. Furthermore, it is not an original result report but a design rationale paper.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Mesenteric Versus Conventional Approach During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma (MAPLE-PD trial): A Multicenter Randomized Controlled Trial. PMID 40772617 · Ann Surg · 2026-Apr-01 The study is an oncology randomized trial with a primary OS endpoint, but it compares two surgical techniques for pancreatic cancer, not drug-containing interventions. Therefore, it does not meet the drug intervention criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Assessing the Impact of Media Coverage of the NordICC Trial on Public Perspectives on Colonoscopy for Colorectal Cancer Screening. PMID 39907707 · J Clin Gastroenterol · 2026-Apr-01 The record describes a survey study assessing public perception of media coverage about a cancer screening trial (NordICC). While it is a randomized study in an oncology context, it does not meet key eligibility criteria: it is not a clinical trial of a drug intervention (the 'intervention' is a media article), it is not a Phase III/IIIb or Phase II/III trial, and it has no time-to-event efficacy endpoint. The primary outcome is a change in intent to undergo colonoscopy, which is a behavioral/attitudinal measure, not a clinical survival or progression endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -